BCL2 and type 1 diabetes mellitus: Specifically, senolytic induction of senescent β cells by two BH3 mimetics, ABT-737 (inhibits Bcl-2, Bcl-xl and Bcl-w) [76] and ABT-199 (a FDA-approved drug which inhibits Bcl-2 specifically) [77], effectively halts T1D development in NOD mice [20].